Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.35 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956284 | 0.72 | ERN1 (0.57) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL31283290 | 0.72 | MAOB (0.33) | LMNAKMT2ATDP1ALDH1A1NFE2L2 | |
| SCHEMBL2636253 | 0.72 | MAOB (0.33) | LMNAKMT2ATDP1ALDH1A1NFE2L2 | |
| SCHEMBL97029 | 0.72 | ERN1 (0.57) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL154794 | 0.72 | ERN1 (0.61) | ERN1MEN1LMNATHRBBLM | |
| Hydrochloric Acid SCHEMBL28530037 | 0.71 | ERN1 (0.55) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL22122728 | 0.71 | ERN1 (0.55) | ERN1MEN1LMNATHRBBLM | |
| Hydrochloric Acid SCHEMBL28546985 | 0.71 | ERN1 (0.55) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL20465749 | 0.71 | — | — | |
| SCHEMBL29540911 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655640-B2 | Camptothecin analogs and methods of preparation thereof | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-02-02 | — | — | US | disclosed |
| US-7514418-B2 | Camptothecin analogs and methods of preparation thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1017399-B1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIV PITTSBURGH (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080269169-A1 | Camptothecin analogs and methods of preparation thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-30 | — | — | US | disclosed |
| EP-1140948-A4 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIV PITTSBURGH (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070259905-A1 | Camptothecin analogs and methods of preparation thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-08 | — | — | US | disclosed |
| US-7271159-B2 | Camptothecin analogs and methods of preparation thereof | UNIVERSITY OF PITTSBURGH (US) | 2007-09-18 | — | — | US | disclosed |
| CN-1177850-C | Camptothecin analogs and methods of preparation thereof | ƥ�ȱ���ѧ | 2004-12-01 | — | — | CN | disclosed |
| US-6743917-B2 | 7-(TRIALKYLSILYLALKYL)-CAMPTOTHECIN OF GIVEN FORMULA BY CYCLIZING A 4-HYDROXY-6-HALO,7-(TRIALKYLSILYLALKYL)-3,4,7,8-TETRAHYDRO-1H-PYRANO(3,4 -C)PYRIDIN-3,8-DIONE WITH AN ARYL ISONITRILE | UNIVERSITY OF PITTSBURGH | 2004-06-01 | — | — | US | disclosed |
| US-20040029835-A1 | Camptothecin analogs and methods of preparation thereof | UNIVERSITY OF PITTSBURGH | 2004-02-12 | — | — | US | disclosed |
| US-20020193598-A1 | Camptothecin analogs and methods of preparation thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-19 | — | — | US | disclosed |
| EP-1017399-A4 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIV PITTSBURGH (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6455699-B1 | SUCH AS (20S)10-HYDROXY-7-TERT-BUTYLDIMETHYLSILYL-CAMPHTOTHECIN; ANTITUMOR AGENTS; SOLUBILITY; BIOAVAILABILITY/ BIODISTRIBUTION | UNIVERSITY OF PITTSBURGH | 2002-09-24 | — | — | US | disclosed |
| CN-1352646-A | Camptothecin analogues and preparation method thereof | UNIV PITTSBURGH (US) | 2002-06-05 | — | — | CN | disclosed |
| EP-1140948-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIVERSITY OF PITTSBURGH (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6150343-A | 10-HYDROXY-7-SUBSTITUTED SILYLCAMPTOTHECIN DERIVATIVE IS USED AS ANTICARCINOGENIC AND ANTITUMOR AGENT | UNIVERSITY OF PITTSBURGH (US) | 2000-11-21 | — | — | US | disclosed |
| US-6136978-A | CYCLIZING SILYL COMPOUND WITH ARYL ISONITRILE COMPOUND TO FORM SILYL CAMPTOTHECIN DERIVATIVE | UNIVERSITY OF PITTSBURGH (US) | 2000-10-24 | — | — | US | disclosed |
| EP-1017399-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | University of Pittsburgh (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-2000035924-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIVERSITY OF PITTSBURGH (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999009996-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIVERSITY OF PITTSBURGH (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193598-A1 | Camptothecin analogs and methods of preparation thereof | TOP1, TOP2A, TOP2B | ERN1 1096/4885MEN1 1072/4885LMNA 654/4885 |
| US-20070259905-A1 | Camptothecin analogs and methods of preparation thereof | ADCY9, BCL9, ADCY10 | ERN1 2107/4885MEN1 2019/4885LMNA 2731/4885 |
| US-20080269169-A1 | Camptothecin analogs and methods of preparation thereof | TOP2A, TOP1, TOP2B | ERN1 3092/4885MEN1 781/4885LMNA 298/4885 |
| US-20040029835-A1 | Camptothecin analogs and methods of preparation thereof | HCCS, ADCY10, TOP2A | ERN1 985/4885MEN1 1117/4885LMNA 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.